ResMed (RMD) Stock Buyback History
TTM buyback yield 1.82% · Shareholder yield (TTM) 1.82%.
RMD
TTM buyback yield
1.82%
Shareholder yield (TTM)
1.82%
5Y share count change
1.2%
TTM buyback spend
$600.04M
SBC coverage (TTM)
5.90x
YoY change in spend
+100.0%
5Y CAGR of spend
N/A
Peak year (2012)
$392.74M
Cumulative spend
$2.07B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- ResMed (RMD) repurchased about $600.04M of stock over the trailing twelve months.
- Diluted share count is up 1.2% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 5.90× — repurchases more than cover SBC dilution.
- TTM repurchases used about 42% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $300.02M | $91.66M | $208.36M | 0.15B | -0.1% | 0.79% |
| 2024 | $150.01M | $80.18M | $69.83M | 0.15B | 0.1% | 0.55% |
| 2023 | $0.00 | $71.14M | −$71.14M | 0.15B | 0.3% | — |
| 2022 | $0.00 | $65.26M | −$65.26M | 0.15B | 0.4% | — |
| 2021 | $0.00 | $63.93M | −$63.93M | 0.15B | 0.5% | — |
| 2020 | $0.00 | $57.56M | −$57.56M | 0.15B | 0.8% | — |
| 2019 | $22.84M | $52.07M | −$29.23M | 0.14B | 0.3% | 0.13% |
| 2018 | $53.80M | $48.41M | $5.39M | 0.14B | 1.1% | 0.36% |
| 2017 | $0.00 | $45.92M | −$45.92M | 0.14B | 0.6% | — |
| 2016 | $102.06M | $46.41M | $55.65M | 0.14B | -0.7% | 1.15% |
| 2015 | $160.30M | $47.85M | $112.44M | 0.14B | -1.2% | 2.02% |
| 2014 | $202.17M | $43.46M | $158.71M | 0.14B | -1.4% | 2.84% |
| 2013 | $186.26M | $38.16M | $148.10M | 0.15B | -1.9% | 2.92% |
| 2012 | $392.74M | $30.59M | $362.16M | 0.15B | -5.0% | 8.82% |
| 2011 | $163.34M | $30.81M | $132.53M | 0.16B | 1.4% | 3.46% |
| 2010 | $131.08M | $29.73M | $101.35M | 0.16B | 0.6% | 2.85% |
| 2009 | $68.59M | $25.52M | $43.08M | 0.15B | -2.0% | 2.24% |
| 2008 | $96.56M | $0.00 | $96.56M | 0.16B | 0.6% | 3.57% |
| 2007 | $2.09M | $0.00 | $2.09M | 0.16B | 1.4% | 0.07% |
| 2006 | $0.00 | $0.00 | $0.00 | 0.15B | 3.0% | — |
| 2005 | $10.97M | $0.00 | $10.97M | 0.15B | 6.7% | 0.48% |
| 2004 | $19.03M | $0.00 | $19.03M | 0.14B | 2.0% | 1.10% |
| 2003 | $3.54M | $0.00 | $3.54M | 0.14B | 1.1% | 0.27% |
| 2002 | $7.87M | $0.00 | $7.87M | 0.14B | 1.8% | 0.86% |
| 2001 | $0.00 | $0.00 | $0.00 | 0.13B | 3.7% | — |
| 2000 | $0.00 | $0.00 | $0.00 | 0.13B | 4.0% | — |
| 1999 | $0.00 | $0.00 | $0.00 | 0.12B | 3.3% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.12B | 2.7% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.12B | 4.1% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.11B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $300.00K | $0.00 | $300.00K | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for ResMed (RMD) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for ResMed (RMD)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for ResMed (RMD)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $300.02M | +100.0% | +$150.01M | ||
| 2024 | $150.01M | — | +$150.01M | ||
| 2023 | $0 | — | $0 | ||
| 2022 | $0 | — | $0 | ||
| 2021 | $0 | — | $0 | ||
| 2020 | $0 | -100.0% | -$22.84M | ||
| 2019 | $22.84M | -57.5% | -$30.96M | ||
| 2018 | $53.80M | — | +$53.80M | ||
| 2017 | $0 | -100.0% | -$102.06M | ||
| 2016 | $102.06M | -36.3% | -$58.24M | ||
| 2015 | $160.30M | -20.7% | -$41.87M | ||
| 2014 | $202.17M | +8.5% | +$15.91M | ||
| 2013 | $186.26M | -52.6% | -$206.49M | ||
| 2012 | $392.74M | +140.4% | +$229.40M | ||
| 2011 | $163.34M | +24.6% | +$32.26M | ||
| 2010 | $131.08M | +91.1% | +$62.49M | ||
| 2009 | $68.59M | -29.0% | -$27.96M | ||
| 2008 | $96.56M | +4515.5% | +$94.47M | ||
| 2007 | $2.09M | — | +$2.09M | ||
| 2006 | $0 | -100.0% | -$10.97M | ||
| 2005 | $10.97M | -42.4% | -$8.06M | ||
| 2004 | $19.03M | +437.2% | +$15.48M | ||
| 2003 | $3.54M | -55.0% | -$4.33M | ||
| 2002 | $7.87M | — | +$7.87M | ||
| 2001 | $0 | — | $0 | ||
| 2000 | $0 | — | $0 | ||
| 1999 | $0 | — | $0 | ||
| 1998 | $0 | — | $0 | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | — | $0 | ||
| 1995 | $0 | -100.0% | -$300,000 | ||
| 1994 | $300,000 | — | +$300,000 | ||
| 1993 | $0 | — | — |
2025's annual buyback spend for ResMed (RMD) came in at $300.02M – surged 100.0% year-over-year.
Across 2015–2025 (10 years), ResMed buyback spend produced a CAGR of +6.5% – sustaining 2 straight years of year-over-year growth.
ResMed buyback spend declined from $392.74M in 2012 to $300.02M in 2025, a 23.6% drawdown.
The highest annual buyback spend of $392.74M was reported in 2012. The lowest in the available history was $0 in 1993.
Among 8 Healthcare peers, ResMed (RMD) ranks 8th; the peer median for buyback spend is $2.75B.
ResMed Buyback Spend 2025: $300.02M
ResMed buyback spend in 2025 was $300.02M, surged 100.0% from 2024.
ResMed Buyback Spend 2024: $150.01M
ResMed buyback spend in 2024 was $150.01M.
ResMed Buyback Spend 2023: $0
ResMed buyback spend in 2023 was $0.
ResMed Buyback Spend 2022: $0
ResMed buyback spend in 2022 was $0.
ResMed Buyback Spend 2021: $0
ResMed buyback spend in 2021 was $0.
See more financial history for ResMed (RMD).
Sector peers by buyback spend
Companies in the same sector as ResMed, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 5.90×.
Capital allocation mix
How ResMed splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.41B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from ResMed's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does ResMed buy back its own stock?
Yes, ResMed (RMD) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does ResMed spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $600.04M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is ResMed's buyback yield?
TTM buyback yield is about 1.82% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is ResMed's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 1.82% combined (TTM-based where available).
Is ResMed diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has ResMed's share count changed?
Diluted weighted average shares changed by about 1.2% over roughly five fiscal years (annual income statement data).
What is ResMed's buyback spend?
Latest reported buyback spend for ResMed (RMD) is $600.04M (period ending March 31, 2026).
How has ResMed buyback spend changed year-over-year?
ResMed (RMD) buyback spend changed +100.0% year-over-year on the latest annual filing.
What is the long-term growth rate of ResMed buyback spend?
ResMed (RMD) buyback spend compound annual growth rate is +6.5% over the most recent 10 years available.
When did ResMed buyback spend hit its highest annual value?
ResMed buyback spend reached its highest annual value of $392.74M in 2012.
What was ResMed buyback spend in 2024?
ResMed (RMD) buyback spend in 2024 was $150.01M.
What was ResMed buyback spend in 2025?
ResMed (RMD) buyback spend in 2025 was $300.02M.
Explore more
RMD Overview
Company profile, financial tools, and key metrics
RMD Revenue Counter
Earns $175.60 every second. See per minute, hour, and day.
RMD Earnings Counter
Earns $48.19 per second net profit. See per minute, hour, and day.
RMD Economic Scale
Exceeds Eswatini's GDP. Compare with world economies.
RMD What If Invested
What if you had invested $1,000? See historical returns from any date.
RMD How It Makes Money
Discover visual breakdown of $5.54B in revenue — where it comes from and where it goes.
RMD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
RMD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
RMD Daily Price Character
Balanced · 50.4% historical win rate (green days). Streaks & record days.
RMD Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.
RMD Dividend Profile
Yield: 1.14%. Safety: 8/8. See full history.
RMD Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
RMD Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
RMD Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
RMD Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.